-
1.发明公开公开(公告)号：US20240127962A1
公开(公告)日：2024-04-18
申请号：US17960560
申请日：2022-10-05
发明人： Peter Kotanko , Ulrike Kotanko , Sabrina Casper , David Joerg , Gudrun Schappacher-Tilp , Doris Fuertinger
CPC分类号： G16H50/50 , G16H50/30 , A61M2205/52 , A61M2230/205 , A61M2230/207
摘要： A computing system for determining a systematic training strategy for the user is provided. The computing system includes a user device that uses one or more sensors to obtain partial pressure of oxygen (PO2) levels of a user over a period of time. The user device provides previous PO2 levels to a personalized erythropoiesis model generation computing platform. The computing platform obtains individualized user data for the user indicating or more previous hematocrit and/or hemoglobin measurements for the user. The computing platform determines an individualized erythropoiesis model for the user based on the one or more previous hematocrit and/or hemoglobin measurements and the previous PO2 information, and employs the individualized erythropoiesis model to determine predicted hematocrit and/or hemoglobin measurements. The computing platform performs one or more actions based on the one or more predicted hematocrit and/or hemoglobin measurements.
-
2.发明公开公开(公告)号：US20240127961A1
公开(公告)日：2024-04-18
申请号：US17960305
申请日：2022-10-05
摘要： A method for determining a next hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) dosage for a first patient using a patient HIF-PHI model is provided. The method includes obtaining population patient data indicating HIF-PHI dosages and hemoglobin measurements for the patients. Then, virtual patient avatars are generated based on the population patient data. Each of the virtual patient avatars indicates a set of personalized model parameters for a HIF-PHI model. A plurality of HIF-PHI models are determined for the virtual patient avatars. Using the HIF-PHI models, one or more HIF-PHI treatment schemes for administering the HIF-PHI dosages is determined. Subsequently, the HIF-PHI treatment schemes along with a hematocrit and/or hemoglobin concentration for a patient are used to determine a next HIF-PHI dosage for the patient, and the next HIF-PHI dosage is administered for the patient.
-
公开(公告)号：US12046375B2
公开(公告)日：2024-07-23
申请号：US17960560
申请日：2022-10-05
发明人： Peter Kotanko , Ulrike Kotanko , Sabrina Casper , David Joerg , Gudrun Schappacher-Tilp , Doris Fuertinger
摘要： A computing system for determining a systematic training strategy for the user is provided. The computing system includes a user device that uses one or more sensors to obtain partial pressure of oxygen (PO2) levels of a user over a period of time. The user device provides previous PO2 levels to a personalized erythropoiesis model generation computing platform. The computing platform obtains individualized user data for the user indicating or more previous hematocrit and/or hemoglobin measurements for the user. The computing platform determines an individualized erythropoiesis model for the user based on the one or more previous hematocrit and/or hemoglobin measurements and the previous PO2 information, and employs the individualized erythropoiesis model to determine predicted hematocrit and/or hemoglobin measurements. The computing platform performs one or more actions based on the one or more predicted hematocrit and/or hemoglobin measurements.
-
公开(公告)号：US20230405201A1
公开(公告)日：2023-12-21
申请号：US18032931
申请日：2021-11-12
发明人： Peter Kotanko , Nadja Grobe , Christoph Zaba , David Joerg , Frank Gebauer
IPC分类号： A61M1/34
CPC分类号： A61M1/3486 , A61M2202/0498
摘要： The described technology may include treatment processes to increase the red blood cell (RBC) population of individuals, particularly chronic kidney disease (CKD) patients with renal anemia, by reducing an amount of Piezo1 chemical agonists in the blood of patients. In one embodiment, a method of treating a patient with renal anemia may include increasing RBC lifespan of an RBC population of the patient via reduction of a Piezo1 channel activation duration of at least a portion of the RBC population by reducing an amount of a target uremic compound in the blood of the patient, the target uremic compound having a form that prolongs the Piezo1 channel activation duration, wherein the amount of the target uremic compound may be reduced via selectively removing at least a portion of the target uremic compound from the blood of the patient. Other embodiments are described.
-
-
-
搜索结果
4 条记录 (耗时 0.02 秒)
